Alumis Inc. Insider Trading

ALMS

Last 12 months

Insiders bought $40.4M and sold $1.57M on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Srinivas Akkaraju sold $1.01M on Sep 8 outside a plan.

Net open-market

+$38.9M

11 buys · 14 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

2 / 7

executives and directors

Last open-market buy

Sep 2026

Sep 8, 2026

Get an email when ALMS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	John R. Schroer Chief Financial Officer	SoldNo plan	794	$6.52	5K	3.2%	Form 4
Nov 2	Sanam Pangali Chief Legal Officer	SoldNo plan	332	$6.52	2K	3.4%	Form 4
Nov 2	Roy C. Hardiman Chief Business & Strategy Ofcr	SoldNo plan	652	$6.52	4K	0.3%	Form 4
Nov 2	David M Goldstein Chief Scientific Officer	SoldNo plan	629	$6.52	4K	0.3%	Form 4
Nov 2	Jorn Drappa Chief Medical Officer	SoldNo plan	593	$6.52	4K	1.0%	Form 4
Nov 2	Mark Christopher Bradley Chief Development Officer	SoldNo plan	623	$6.52	4K	0.9%	Form 4
Sep 4 – 8	Srinivas Akkaraju Director	Bought 4 parts	986,721	$10.87 average	$10.7M	16%	Form 4
Sep 8	Srinivas Akkaraju Director	SoldNo plan 2 parts	96,131	$10.55 average	$1.01M	1.3%	Form 4
Aug 3	Sanam Pangali Chief Legal Officer	SoldNo plan	1,364	$26.37	36K	12%	Form 4
Aug 3	Mark Christopher Bradley Chief Development Officer	SoldNo plan	2,572	$26.37	68K	3.6%	Form 4
Aug 3	Jorn Drappa Chief Medical Officer	SoldNo plan	2,447	$26.37	65K	4.1%	Form 4
Aug 3	David M Goldstein Chief Scientific Officer	SoldNo plan	2,596	$26.37	68K	1.0%	Form 4
Aug 3	John R. Schroer Chief Financial Officer	SoldNo plan	3,282	$26.37	87K	12%	Form 4
Aug 3	Roy C. Hardiman Chief Business & Strategy Ofcr	SoldNo plan	2,692	$26.37	71K	1.2%	Form 4
Jul 6	Sanam Pangali Chief Legal Officer	SoldNo plan	5,000	$28.00	140K	31%	Form 4
Jan 9	Srinivas Akkaraju Director	Bought	588,235	$17.00	$10M	10%	Form 4
Jan 8	Foresite Labs, LLC Large holder	Bought 2 parts	411,764	$17.00 average	$7M	16%	Form 4
Jan 8	Foresite Labs Fund I, L.p. Large holder	Bought 2 parts	411,764	$17.00 average	$7M	16%	Form 4
Jan 8	James B. Tananbaum Director	Bought 2 parts	411,764	$17.00 average	$7M	16%	Form 4
Dec 5, 2025	Srinivas Akkaraju Director	Bought 3 parts	186,377	$9.84 average	$1.83M	3.3%	Form 4
Dec 2, 2025 – Dec 4, 2025	Srinivas Akkaraju Director	Bought 3 parts	262,027	$7.79 average	$2.04M	4.9%	Form 4
Nov 26, 2025 – Dec 1, 2025	Srinivas Akkaraju Director	Bought 3 parts	173,589	$7.55 average	$1.31M	3.4%	Form 4
Nov 21, 2025	Foresite Labs Fund I, L.p. Large holder	Bought	72,212	$7.38	533K	2.8%	Form 4
Nov 21, 2025	James B. Tananbaum Director	Bought	72,212	$7.38	533K	2.8%	Form 4
Nov 21, 2025	Foresite Labs Affiliates 2021, LLC Large holder	Bought	72,212	$7.38	533K	2.8%	Form 4
Nov 20, 2025	Srinivas Akkaraju Director	Bought	125,743	$7.20	905K	2.5%	Form 4
Nov 17, 2025 – Nov 19, 2025	Srinivas Akkaraju Director	Bought 3 parts	241,338	$6.34 average	$1.53M	5.1%	Form 4
Nov 17, 2025 – Nov 19, 2025	Foresite Labs Affiliates 2021, LLC Large holder	Bought 4 parts	507,874	$6.09 average	$3.09M	25%	Form 4
Nov 17, 2025 – Nov 19, 2025	Foresite Capital Management VI LLC Large holder	Bought 4 parts	507,874	$6.09 average	$3.09M	25%	Form 4
Nov 17, 2025 – Nov 19, 2025	James B. Tananbaum Director	Bought 4 parts	507,874	$6.09 average	$3.09M	25%	Form 4
Nov 13, 2025	Srinivas Akkaraju Director	Bought	276,179	$5.25	$1.45M	6.1%	Form 4
May 2, 2025 – May 6, 2025	James B. Tananbaum Director	Bought 2 parts	45,000	$4.50 average	202K	1.1%	Form 4
May 2, 2025 – May 6, 2025	Foresite Labs Affiliates 2021, LLC Large holder	Bought 2 parts	45,000	$4.50 average	202K	1.1%	Form 4
May 2, 2025 – May 6, 2025	Foresite Labs Management I, LLC Large holder	Bought 2 parts	45,000	$4.50 average	202K	1.1%	Form 4
May 2, 2025 – May 5, 2025	Srinivas Akkaraju Director	Bought 3 parts	320,290	$4.61 average	$1.48M	9.8%	Form 4
Apr 1, 2025 – Apr 2, 2025	Alan Colowick Director	Bought 2 parts	18,404	$7.03 average	129K	New	Form 4
Apr 1, 2025	Martin Babler President, CEO and Chairman	Bought	15,650	$6.44	101K	17%	Form 4

Nov 2No plan
John R. Schroer
Chief Financial Officer · sold 794 at $6.52
5K
3.2% of stake
Nov 2No plan
Sanam Pangali
Chief Legal Officer · sold 332 at $6.52
2K
3.4% of stake
Nov 2No plan
Roy C. Hardiman
Chief Business & Strategy Ofcr · sold 652 at $6.52
4K
0.3% of stake
Nov 2No plan
David M Goldstein
Chief Scientific Officer · sold 629 at $6.52
4K
0.3% of stake
Nov 2No plan
Jorn Drappa
Chief Medical Officer · sold 593 at $6.52
4K
1.0% of stake
Nov 2No plan
Mark Christopher Bradley
Chief Development Officer · sold 623 at $6.52
4K
0.9% of stake
Sep 4 – 8
Srinivas Akkaraju
Director · bought 986,721 at avg $10.87
$10.7M
16% of stake
Sep 8No plan
Srinivas Akkaraju
Director · sold 96,131 at avg $10.55
$1.01M
1.3% of stake
Aug 3No plan
Sanam Pangali
Chief Legal Officer · sold 1,364 at $26.37
36K
12% of stake
Aug 3No plan
Mark Christopher Bradley
Chief Development Officer · sold 2,572 at $26.37
68K
3.6% of stake
Aug 3No plan
Jorn Drappa
Chief Medical Officer · sold 2,447 at $26.37
65K
4.1% of stake
Aug 3No plan
David M Goldstein
Chief Scientific Officer · sold 2,596 at $26.37
68K
1.0% of stake
Aug 3No plan
John R. Schroer
Chief Financial Officer · sold 3,282 at $26.37
87K
12% of stake
Aug 3No plan
Roy C. Hardiman
Chief Business & Strategy Ofcr · sold 2,692 at $26.37
71K
1.2% of stake
Jul 6No plan
Sanam Pangali
Chief Legal Officer · sold 5,000 at $28.00
140K
31% of stake
Jan 9
Srinivas Akkaraju
Director · bought 588,235 at $17.00
$10M
10% of stake
Jan 8
Foresite Labs, LLC
Large holder · bought 411,764 at avg $17.00
$7M
16% of stake
Jan 8
Foresite Labs Fund I, L.p.
Large holder · bought 411,764 at avg $17.00
$7M
16% of stake
Jan 8
James B. Tananbaum
Director · bought 411,764 at avg $17.00
$7M
16% of stake
Dec 5, 2025
Srinivas Akkaraju
Director · bought 186,377 at avg $9.84
$1.83M
3.3% of stake
Dec 2, 2025 – Dec 4, 2025
Srinivas Akkaraju
Director · bought 262,027 at avg $7.79
$2.04M
4.9% of stake
Nov 26, 2025 – Dec 1, 2025
Srinivas Akkaraju
Director · bought 173,589 at avg $7.55
$1.31M
3.4% of stake
Nov 21, 2025
Foresite Labs Fund I, L.p.
Large holder · bought 72,212 at $7.38
533K
2.8% of stake
Nov 21, 2025
James B. Tananbaum
Director · bought 72,212 at $7.38
533K
2.8% of stake
Nov 21, 2025
Foresite Labs Affiliates 2021, LLC
Large holder · bought 72,212 at $7.38
533K
2.8% of stake
Nov 20, 2025
Srinivas Akkaraju
Director · bought 125,743 at $7.20
905K
2.5% of stake
Nov 17, 2025 – Nov 19, 2025
Srinivas Akkaraju
Director · bought 241,338 at avg $6.34
$1.53M
5.1% of stake
Nov 17, 2025 – Nov 19, 2025
Foresite Labs Affiliates 2021, LLC
Large holder · bought 507,874 at avg $6.09
$3.09M
25% of stake
Nov 17, 2025 – Nov 19, 2025
Foresite Capital Management VI LLC
Large holder · bought 507,874 at avg $6.09
$3.09M
25% of stake
Nov 17, 2025 – Nov 19, 2025
James B. Tananbaum
Director · bought 507,874 at avg $6.09
$3.09M
25% of stake
Nov 13, 2025
Srinivas Akkaraju
Director · bought 276,179 at $5.25
$1.45M
6.1% of stake
May 2, 2025 – May 6, 2025
James B. Tananbaum
Director · bought 45,000 at avg $4.50
202K
1.1% of stake
May 2, 2025 – May 6, 2025
Foresite Labs Affiliates 2021, LLC
Large holder · bought 45,000 at avg $4.50
202K
1.1% of stake
May 2, 2025 – May 6, 2025
Foresite Labs Management I, LLC
Large holder · bought 45,000 at avg $4.50
202K
1.1% of stake
May 2, 2025 – May 5, 2025
Srinivas Akkaraju
Director · bought 320,290 at avg $4.61
$1.48M
9.8% of stake
Apr 1, 2025 – Apr 2, 2025
Alan Colowick
Director · bought 18,404 at avg $7.03
129K
New position
Apr 1, 2025
Martin Babler
President, CEO and Chairman · bought 15,650 at $6.44
101K
17% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ALMS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ALMS

CompareIntrinsic value

ROIVRoivant Sciences Ltd

$38.23+6.08%16

ADAGAdagene Inc.

$2.41+2.55%25

OVIDOvid Therapeutics Inc.

$2.74+14.17%25

NAMSNewAmsterdam Pharma Co. N.V.

$20.93+5.18%10

COYACoya Therapeutics Inc.

$3.08-0.96%10

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

HCWBHCW Biologics Inc.

$1.08-6.09%15

ABEOAbeona Therapeutics Inc.

$4.22-0.71%40

Held by ETFs

ALMS is in 36 US ETFs. The largest of them, with ALMS's weight in each:

Spot a number that looks wrong? Check it in ALMS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ALMS

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.